Our Team

Matt has been a healthcare-focused venture capital investor since 1980. He began his venture capital career with Citicorp Venture Capital, where he was VP and a member of the investment executive committee. Matt later joined Robertson, Stephens & Co. and was partner and Chairman of the Venture Capital Group. In 1991, he formed Mackowski & Shepler, an investment partnership focused on developing life science and medical technology companies and the predecessor to Telegraph Hill Partners (THP). Matt has represented THP on the boards of Kinetikos Medical (acquired by Integra), Ambion (acquired by Applied Biosystems), Aurora Discovery (acquired by NEXUS Biosystems), Interface Associates (acquired by NDC), Asuragen, Althea Technologies (acquired by Ajinomoto), AltheaDx, MedPricer, Magstim and TrakCel. Matt received a BA from Duke University and an MBA from The Wharton School.

Kevin has extensive knowledge and experience in health care and health care transactions. His primary goal is to help small and medium sized health care companies grow successfully and maximize their value. Kevin has a law degree and an MBA from the University of Minnesota. His experience spans law, healthcare, and mergers and acquisitions, having participated in over 70 transactions.

Dave is a veteran of the health care industry and is a seasoned CEO and founder. Prior to co-founding Emerging Therapy Solutions, Dave led several managed care technology companies, including Medication Management Systems, Inc. (acquired by Genoa HealthCare), NovoLogix (acquired by CVS), and RxHub. Previously, Dave was CEO of United Resource Networks at United Health Group, a business that managed organ and tissue transplants for 45 million payer lives, and SVP at American MedCenters, an HMO management company. Dave holds a BS in Pharmacy from Ohio State University and a Ph.D. from the University of Minnesota.

Ravi is a seasoned executive and founder with a strong background in finance and healthcare and clinical services. Prior to TrakCel, Ravi was the CFO of Biotec Services International and has extensive leadership experience in finance, health, biotech, safety, and environmental functions. Ravi has a BSc in Biochemistry and Molecular Biology from Cardiff University.

Jeanette has worked in the areas of private equity, mergers & acquisitions, securities law and administration since 1990. Prior to joining Telegraph Hill Partners (THP) in 2004, Jeanette worked at Three Cities Research, a private equity firm in New York focused on middle market companies. Prior to joining Three Cities Research, Jeanette practiced law at Epstein, Becker & Green P.C. in New York where she focused on corporate and securities law. Before commencing her legal career, Jeanette was part of the M&A department of Société Générale Securities Corporation. She has represented THP on the boards of Interface Associates (acquired by NDC), AngioScore (acquired by Spectranetics), and Medpricer (acquired by Premier). She is currently on the boards of TrakCel, Magstim and Emerging Therapy Solutions. Jeanette has a Bachelor of Art degree in Philosophy from Hunter College, City University of New York and a Juris Doctor from Fordham University School of Law.